1) It has been financed by people who have a whole lot of shares to dump on any positive news. They can then issue these same people more shares, up to 150 million total issued.
2) There has been no independent public documentation of the compassionate use patients.
3) IGF factors in general are KNOWN to have long term negative effects.
4) The rush into the P2b on scanty human trials.
Also see my sticky.
Yes the drug may work, but with the share structure I see very little potential for anyone buying on the open market to make money on a long term investment.
Market Data 
Markets 
AI
